Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Inflammatory Bowel Disease IV: Pharmacological Management

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...

Drugs for Treatment of Diarrhea-Predominant IBS

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...

Urinary Tract Infection IV: Nursing Management

Urinary Tract Infection IV: Nursing Management

In managing urinary tract infections (UTIs) in nursing, a comprehensive assessment is essential. Begin by gathering subjective data, such as the patient’s complaints of dysuria (painful urination), urinary frequency, urgency, suprapubic pain, and any lower abdominal discomfort. This information can be complemented by questions regarding previous UTIs, sexual activity, and personal hygiene practices, which can provide insight into risk factors. Objective assessment should focus on signs like...

Drugs for Treatment of Ulcerative Colitis in IBD

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.

Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents

Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents

Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...

Endocarditis III: Medical Management

Endocarditis III: Medical Management

Infective endocarditis management involves a multifaceted approach encompassing infection prevention, lifestyle modifications, pharmacological therapy, and surgical management.Infection Prevention:Hand Hygiene: Thorough handwashing is crucial to prevent the spread of infection. Hand hygiene should be performed regularly, especially before and after using the restroom.Oral Hygiene: Good oral hygiene is essential. It includes brushing teeth immediately after waking up and before bed, flossing...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Potentially inappropriate medication use and mortality in patients with cognitive impairment.

European journal of clinical pharmacology·2022

Same author

Documentation of Do-Not-Attempt-Cardiopulmonary-Resuscitation orders amid the COVID-19 pandemic.

Age and ageing·2021

Same author

A Case of Overlap Posterior Cortical Atrophy and Logopenic Variant Primary Progressive Aphasia.

The neurologist·2019

Same author

Suboptimal lipid management before and after ischaemic stroke and TIA-the North Dublin Population Stroke Study.

Irish journal of medical science·2018

Same author

Identified mental disorders in older adults in primary care: A cross-sectional database study.

The European journal of general practice·2018

Same author

Training doctors to manage patients with multimorbidity: a systematic review.

Journal of comorbidity·2017

Search research articles

Related Experiment Video

Updated: Jun 6, 2026

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment

Published on: May 25, 2017

Update on Clostridium difficile infection.

Caoilfhionn O'Donoghue¹, Lorraine Kyne

¹Department of Medicine for the Older Person, Mater Misericordiae University Hospital, Ireland.

Current Opinion in Gastroenterology

|November 25, 2010

Summary

This summary is machine-generated.

Clostridium difficile infection (CDI) is evolving with new hypervirulent strains and increasing rates in the community. Novel treatments, including fidaxomicin and monoclonal antibodies, show promise for managing CDI and reducing recurrence.

More Related Videos

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

Published on: December 8, 2014

Related Experiment Videos

Last Updated: Jun 6, 2026

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment

Published on: May 25, 2017

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

Published on: December 8, 2014

Area of Science:

Infectious Diseases
Epidemiology
Microbiology

Background:

Clostridium difficile infection (CDI) epidemiology is shifting, marked by the rise of hypervirulent strains.
CDI incidence is increasing in community settings, pediatric populations, and among individuals with inflammatory bowel disease.

Purpose of the Study:

To review current epidemiological data on Clostridium difficile infection (CDI).
To summarize recent advancements in the pathogenesis, diagnosis, and treatment of CDI.

Main Methods:

Literature review of recent epidemiological studies and clinical trials.
Analysis of emerging Clostridium difficile strains and their impact.
Evaluation of new therapeutic agents and updated clinical guidelines.

Main Results:

Emergence of hypervirulent strains, including PCR ribotype 078, linked to community-associated CDI and found in food products.
While the NAP1/BI/027 strain remains prevalent in North America, its dominance is decreasing in Europe.
New guidelines from SHEA and IDSA offer updated recommendations for CDI management.
Promising results from novel therapies like fidaxomicin and monoclonal antibodies against toxins A and B for CDI treatment and recurrence reduction.

Conclusions:

Significant progress has been made in understanding the transmission and pathogenesis of Clostridium difficile.
New therapeutic strategies are emerging, offering improved options for treating CDI and preventing its recurrence.